PRRT2 and breast cancer: Cinnarizine is a potential drug that targets protein kinase C (PKC), interferes with the cell cycle of breast cancer cells (reducing S-phase cells and increasing G1-phase cell accumulation), damages the mitochondrial membrane potential, releases cyt c into the cytoplasm, and activates caspase-3, which inhibits the growth of breast cancer cells by inducing apoptosis [58].